NCT05752877View on ClinicalTrials.gov

Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma

NARecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Advanced GliomaComplication of Chimeric Antigen Receptor (CAR-T) Cell Therapy
Interventions
BIOLOGICAL

Targeted IL-13 Rα2 UCAR-T cell injection

local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.

BIOLOGICAL

Targeted B7-H3 UCAR-T cell injection

local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.

Trial Locations (1)

215004

RECRUITING

The Second Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

Soochow T-Maximun Biotechnology Co. LTD

UNKNOWN

lead

Second Affiliated Hospital of Soochow University

OTHER